A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes

NCT02020616 · Terminated

Last updated 2026-05-28

This clinical trial tested the safety and effectiveness of the drug LY3053102 in adults with type 2 diabetes to see how it affects their blood sugar levels over a 12-week period.

Status Terminated Stopped early and will not restart.

Phase Phase1, Phase2

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 60 people

Who can join Ages 21+ · all sexes

Timeline Started 2013-12 · est. completion 2015-02

Where 5 sites · United States

What this study is testing ClinicalTrials.gov NCT02020616 ↗

Description as written by the study sponsor.

The purpose of this study is to investigate the safety and effectiveness of the study drug known as LY3053102 in participants with Type 2 diabetes mellitus. The study drug will be given in different doses as an injection under the skin. The study is expected to last up to 6 months for each participant. Participants may remain on stable-dose metformin as prescribed by their personal physician.

Treatments tested

LY3053102 Drug

Administered SC
Exenatide ER Drug

Administered SC
Placebo Drug

Administered SC
Metformin Drug

Administered orally (PO)

Main thing measured	Change From Baseline in Hemoglobin A1c (HbA1c) at 12-Week Endpoint
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02020616 ↗